U.S. Markets closed
  • S&P Futures

    4,166.75
    -2.25 (-0.05%)
     
  • Dow Futures

    34,267.00
    -51.00 (-0.15%)
     
  • Nasdaq Futures

    13,389.75
    +2.75 (+0.02%)
     
  • Russell 2000 Futures

    2,217.50
    -5.20 (-0.23%)
     
  • Crude Oil

    65.62
    +0.25 (+0.38%)
     
  • Gold

    1,850.70
    +12.60 (+0.69%)
     
  • Silver

    27.69
    +0.33 (+1.21%)
     
  • EUR/USD

    1.2136
    -0.0010 (-0.0850%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • Vix

    18.81
    -4.32 (-18.68%)
     
  • GBP/USD

    1.4085
    -0.0017 (-0.1239%)
     
  • USD/JPY

    109.3300
    -0.0170 (-0.0155%)
     
  • BTC-USD

    44,722.42
    -3,365.50 (-7.00%)
     
  • CMC Crypto 200

    1,238.16
    -120.40 (-8.86%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    27,983.49
    -100.98 (-0.36%)
     

Sucampo presents data for AMITIZA for treatment of IBS-C

Sucampo Pharmaceuticals announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA(lubiprostone) for the treatment of irritable bowel syndrome with constipation, IBS-C, at Digestive Disease Week 2012 in San Diego. This analysis of patients presenting with moderate to very severe abdominal pain and fewer than three weekly spontaneous bowel movements, SBMs, at baseline demonstrates that AMITIZA provides a statistically significantly higher proportion of patients with consistent relief from IBS-C symptoms (greater than 30% improvement from baseline in abdominal pain ratings and normalization of bowel frequency for 9 of the 12 treatment weeks) as compared